Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine episode artwork

EPISODE · Mar 12, 2025 · 17 MIN

Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine

from BiotechTV - News · host BiotechTV

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.

NOW PLAYING

Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine

0:00 17:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 17 minutes long.

When was this BiotechTV - News episode published?

This episode was published on March 12, 2025.

What is this episode about?

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!